21:40 , Jan 3, 2018 |  BC Innovations  |  Product R&D

Expanding small molecule horizons

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco...
17:57 , Sep 14, 2017 |  BC Innovations  |  Emerging Company Profile

RNA gets CRISPR

Two of the outstanding hurdles for CRISPR-based gene editing are the safety concerns of permanently changing the cell’s DNA and the efficacy limitations of relying on natural DNA repair mechanisms to fix the cuts. Locana...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01,...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Mining Quebec

An option deal with Roche (SIX:ROG; OTCQX:RHHBY) marks the first potential exit for early stage life science venture fund AmorChem and its in-house medicinal chemistry CRO, NuChem Therapeutics Inc. The deal gives Roche an option for...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Roche, AmorChem deal

Roche partnered with VC fund AmorChem to discover small molecules to treat myotonic muscular dystrophy type 1. Discovery will take place at AmorChem’s medicinal chemistry incubator NuChem Therapeutics Inc. using technology discovered by University...
01:12 , Jul 30, 2014 |  BC Extra  |  Company News

Roche, AmorChem partner for myotonic muscular dystrophy

Roche (SIX:ROG; OTCQX:RHHBY) partnered with VC fund AmorChem L.P. (Montreal, Quebec) to discover small molecules to treat myotonic muscular dystrophy type 1. Discovery will take place at AmorChem's medicinal chemistry incubator NuChem Therapeutics Inc. using...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

ISIS-DMPKRx: Phase I started

Isis began a Phase I trial of ISIS-DMPKRx. The start triggered a $14 million milestone payment to Isis from Biogen Idec Inc. (NASDAQ:BIIB, Weston, Mass.) under a June 2012 deal granting Biogen Idec an...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy Dystrophia myotonica protein kinase (DMPK) In vitro and mouse studies identified a DMPK CUG...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Biogen Idec, Isis Pharmaceuticals deal

Isis received a $10 million milestone payment from Biogen under a June 2012 deal to develop and commercialize an antisense drug candidate targeting dystrophia myotonica-protein kinase ( DMPK; DM1) to treat myotonic dystrophy type...